The initial success of Sildenafil undeniably transformed the pharmaceutical landscape, but investing in companies primarily reliant on off-patent versions presents a uncertain picture. While early earnings were substantial, the cessation of patents and the rise of discounted alternatives have eroded the customer base. Thus, a thorough assessment of